Life Sciences Cos. Should Look Past Litigation During COVID
Disputes between business partners have always been particularly disruptive for life sciences companies.
Long-term, complex relationships with multiple research, development and commercialization partners; global supply chains; lengthy times to market involving massive investment and risk; and other features have always made litigation and lengthy, litigation-lite arbitrations problematic.
Full Article Below:
Disputes between business partners have always been particularly disruptive for life sciences companies.
Long-term, complex relationships with multiple research, development and commercialization partners; global supply chains; lengthy times to market involving massive investment and risk; and other features have always made litigation and lengthy, litigation-lite arbitrations problematic.
Full Article Below:
Related Topics
Latest Insights
Stay Connected
Sign up to hear about upcoming events or to access information or recordings of past events and webinars.